Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood (2023) 142 (Supplement 1): 3267.

https://doi.org/10.1182/blood-2023-188084

Published: 2023

Journal Articles

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2023) 142 (Supplement 1): 322.

https://doi.org/10.1182/blood-2023-190693

Published: 2023

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Blood (2023) 142 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2023-189711

Published: 2023

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Blood (2022) 140 (Supplement 1): 234–237.

https://doi.org/10.1182/blood-2022-170850

Published: 2022

Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood (2022) 140 (Supplement 1): 11698–11701.

https://doi.org/10.1182/blood-2022-170049

Published: 2022

Journal Articles

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Tareq Abuasab, Fadi Haddad, Shehab Fareed Mohamed, Jeffrey L. Jorgensen, Sa A Wang, Philip A. Thompson, Tapan M. Kadia, Yesid Alvarado, Sherry A. Pierce, Michael J. Keating, David McCue, Hagop Kantarjian, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9385–9386.

https://doi.org/10.1182/blood-2022-165639

Published: 2022

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A ( MLL ) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Sergej Konoplev, Guilin Tang, Xiaoqiong Wang, Wei Wang, Beenu Thakral, Jie Xu, Sherry A. Pierce, Jeffrey L. Jorgensen, Farhad Ravandi, Ghayas C. Issa, Olga Pozdnyakova, Sa A Wang, Robert P. Hasserjian

Blood (2021) 138 (Supplement 1): 793.

https://doi.org/10.1182/blood-2021-153749

Published: 2021

Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2021-154074

Published: 2021

Journal Articles

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Sangeetha Venugopal, Nicholas J. Short, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Sherry A. Pierce, Sanam Loghavi, Keyur P. Patel, Ghayas C. Issa, Hagop Kantarjian, Sa A Wang, Farhad Ravandi

Blood (2021) 138 (Supplement 1): 2374.

https://doi.org/10.1182/blood-2021-154105

Published: 2021

Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2021-154022

Published: 2021

Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2021-154155

Published: 2021

Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Blood (2021) 138 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2021-154454

Published: 2021

Journal Articles

Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1- mutated Acute Myeloid Leukemia

Sanam Loghavi, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Rashmi Kanagal-Shamanna, MD, Tomoyuki Tanaka, MDPhD, Ken Furudate, DDM, PhD, Nicholas J. Short, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Noushin Farnoud, PhD, Sherry A. Pierce, BSN, BA, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Keyur P. Patel, MBBS, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Sa A Wang, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139871

Published: 2020

Journal Articles

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-142121

Published: 2020

Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Blood (2020) 136 (Supplement 1): 9–11.

https://doi.org/10.1182/blood-2020-138565

Published: 2020

Journal Articles

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Keyur Patel, MD PhD, Steven M. Kornblau, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Partow Kebriaei, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Jairo A. Matthews, Munazza Noor, Rebecca Garris, MSc, Farhad Ravandi, MBBS, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-141971

Published: 2020

Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-139896

Published: 2020

NARROW

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A ( MLL ) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Prognostic Value of Measurable Residual Disease Assessed By Multiparameter Flowcytometry in Patients with NPM1-Mutated Acute Myeloid Leukemia

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1- mutated Acute Myeloid Leukemia

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only